Literature DB >> 2110206

A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder.

J Cottraux1, E Mollard, M Bouvard, I Marks, M Sluys, A M Nury, R Douge, P Cialdella.   

Abstract

DSM-3 obsessive-compulsive out-patients were randomly assigned to fluvoxamine with antiexposure (F), fluvoxamine with exposure (Fe), or placebo with exposure (Pe) for 24 weeks. Of 65 patients offered treatment 60 entered the trial, 50 reached week 8, 44 completed treatment to week 24, and 37 reached follow up to week 48. On average the patient had depressed mood (mean Hamilton depression rating scale = 19). Drop-out numbers, clinical status and behavioural measures were comparable across groups. Most F patients did not do antiexposure, but Fe and Pe patients complied in doing exposure. All three groups improved in rituals and depression from week 0 to week 24 and 48, with a slight but non-significant superiority for combined treatment up to week 24. At week 8 there was a drug between-group effect on rituals, but not on depression. At week 24 there was a drug between-group effect on depression, but not on rituals. The drug superiority was short-lived. At week 48 there was no between-group difference in rituals or depression. Depression was related to ritual outcome at week 24 in F, and tended to be so in Fe.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2110206     DOI: 10.1097/00004850-199001000-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  13 in total

Review 1.  A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder.

Authors:  Dan J Stein; Nastassja Koen; Naomi Fineberg; Leonardo F Fontenelle; Hisato Matsunaga; David Osser; H Blair Simpson
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Selective serotonin reuptake inhibitors.

Authors:  J G Edwards
Journal:  BMJ       Date:  1992-06-27

Review 3.  Serotonin selectivity for obsessive compulsive and panic disorders.

Authors:  S A Montgomery; T Bullock; N Fineberg
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

4.  Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial.

Authors:  Michael Rufer; Iver Hand; Heike Alsleben; Anne Braatz; Jürgen Ortmann; Birgit Katenkamp; Susanne Fricke; Helmut Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-12       Impact factor: 5.270

Review 5.  Cognitive behavioral therapy for obsessive-compulsive disorder: an update.

Authors:  Jonathan D Huppert; Martin E Franklin
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

6.  Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review.

Authors:  Stefan G Hofmann; Alice T Sawyer; Kristina J Korte; Jasper A J Smits
Journal:  Int J Cogn Ther       Date:  2009-01-01

Review 7.  Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).

Authors:  G M Soomro; D Altman; S Rajagopal; M Oakley-Browne
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

8.  Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder.

Authors:  Eric A Storch; Regina Bussing; Brent J Small; Gary R Geffken; Joseph P McNamara; Omar Rahman; Adam B Lewin; Cynthia S Garvan; Wayne K Goodman; Tanya K Murphy
Journal:  Behav Res Ther       Date:  2013-10-10

9.  A promising randomized trial of a new therapy for obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; You-Sheng Wen; Jian-Dong Ma; Dong-Ming Han; Yu-Xia Li; Shu-Fan Wang
Journal:  Brain Behav       Date:  2012-06-26       Impact factor: 2.708

Review 10.  Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders.

Authors:  John M Kuzma; Donald W Black
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.